Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 26 of 32 for:    Recruiting, Not yet recruiting, Available Studies | obesity | stimulation

Effect of Lifestyle and/or Metformin Intervention on Pregnancy Outcome, A Pilot Randomized Controlled Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03898037
Recruitment Status : Recruiting
First Posted : April 1, 2019
Last Update Posted : August 9, 2019
Sponsor:
Information provided by (Responsible Party):
Reproductive & Genetic Hospital of CITIC-Xiangya

Brief Summary:
The purpose of pilot trial is to compare the efficacy of lifestyle intervention, metformin intervention, lifestyle combined with metformin intervention in improving assisted reproductive technology in non-polycystic ovary syndrome(pcos) patients with overweight/obesity and insulin resistance compared with conventional clinical education. Subjects who meet the inclusion criteria will be randomized to four groups: lifestyle intervention group, metformin intervention group, lifestyle combined with metformin intervention group, and routine clinical education group. Subjects of above three intervention group will start ovulation stimulation treatment after reach the aim or duration of intervention and routine clinical education group has no intervention. All subjects are treated with the same procedures, including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos. The primary outcome is ongoing pregnancy rate.

Condition or disease Intervention/treatment Phase
Infertility, Female Obesity Insulin Resistance Behavioral: weight loss intervention Drug: metformin intervention Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Lifestyle and/or Metformin Intervention on Pregnancy Outcome in Overweight/Obese Non-pcos Infertility Women With Insulin Resistance , A Pilot Randomized Controlled Trial
Actual Study Start Date : June 13, 2019
Estimated Primary Completion Date : March 31, 2021
Estimated Study Completion Date : June 30, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Infertility

Arm Intervention/treatment
Experimental: lifestyle intervention group

Subjects will receive weight loss intervention under the guidance of a dietitian after assigned to lifestyle intervention group, including: restricted energy balanced diet, aerobic exercise, etc. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test oral glucose tolerance test (OGTT)/insulin resistance test(IRT)/HOMA, blood routine, liver and kidney function on the day of grouping and in the 4th week, the 8th week, the 12th week after grouping.

The aim is to lose 5-10% of the initial body weight. If the target was reached within 3 months, subjects will receive ovarian stimulation treatment in advance, otherwise treatment starts after 3 months. All subjects are treated with the same procedures,including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos. The pregnancy and perinatal outcomes after transfer were followed up.

Behavioral: weight loss intervention
weight loss intervention under the guidance of a dietitian, including: restricted energy balanced diet, aerobic exercise, etc.

Experimental: metformin intervention group

Subjects will be given metformin intervention with a starting dose of 0.5g bid after assigned to metformin intervention group, and the dose will be adjusted by doctors according to the insulin level and adverse events. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and the 4th week, the 8th week, the 12th week after grouping.

The aim is to adjust insulin level to normal within 3 months. If the target was reached within 3 months, subjects will start to receive ovarian stimulation treatment in advance, Otherwise treatment starts after 3 months. All subjects are treated with the same procedures, including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up.

Drug: metformin intervention
metformin intervention with a starting dose of 0.5g bid, and the dose will be adjusted by doctors according to the patient's insulin level and adverse events.

Experimental: lifestyle combined with metformin intervention group

Subjects will receive weight loss intervention and metformin intervention after assigned to lifestyle combined with metformin intervention group. Subjects will come to the hospital to measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and in the 4th week, the 8th week, the 12th week after grouping.

The aim is to lose 5-10% of the initial body weight and adjust insulin level to normal within 3 months. If the target was reached within 3 months, subjects will receive ovarian stimulation treatment in advance, otherwise treatment starts after 3 months. All subjects are treated with the same procedures,including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up.

Behavioral: weight loss intervention
weight loss intervention under the guidance of a dietitian, including: restricted energy balanced diet, aerobic exercise, etc.

Drug: metformin intervention
metformin intervention with a starting dose of 0.5g bid, and the dose will be adjusted by doctors according to the patient's insulin level and adverse events.

No Intervention: routine clinical education group
Subjects will only accept clinical routine education after assigned to routine clinical education group. Subjects will measure their height, weight, waist circumference, hip circumference, body fat rate, BMI and test OGTT/IRT/HOMA, blood routine, liver and kidney function on the day of grouping and will start induced ovulation therapy after completing routine clinical examination. All subjects are treated with the same procedures,including a long ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned transfer of two day-3 embryos etc. The pregnancy and perinatal outcomes after transfer were followed up.



Primary Outcome Measures :
  1. Ongoing Pregnancy Rate [ Time Frame: 8 months ]

    Number of women with ongoing pregnancy / number of women randomized to the specific group.

    Ongoing pregnancy was defined as the presence of a fetus with heart motion at 10 to 12 weeks of gestation.



Secondary Outcome Measures :
  1. Number of eggs obtained [ Time Frame: 5 months ]
    The total number of oocytes obtained after one treatment cycle

  2. Biochemical Pregnancy Rate [ Time Frame: 5 months ]

    Number of women with Biochemical pregnancy /number of women randomized to the specific group.

    Biochemical pregnancy was defined as a human chorionic gonadotropin level of more than 10 milli-International unit(mIU)per milliliter(ml), as measured at about 14 days after embryo transfer.


  3. Clinical Pregnancy Rate [ Time Frame: 6 months ]
    Number of women with clinical pregnancies /number of women randomized to the specific group. Clinical pregnancy was defined as the presence of a gestational sac in the uterine cavity at about 28 days after embryo transfer, as detected on ultrasonography.

  4. Live birth rate [ Time Frame: 16 months ]

    Number of women with live births / number of women randomized to the specific group.

    Live birth is defined as the delivery of any viable infant at 28 weeks or more of gestation after our interventions.


  5. Duration of pregnancy [ Time Frame: 16 months ]
    The time from the first day of last menstrual period to the day of delivery.

  6. Birth weight [ Time Frame: 16 months ]
    Weight of newborns at delivery.

  7. Pregnancy Loss Rate [ Time Frame: 12 months ]
    Number of pregnancy losses / number of clinical pregnancies. Pregnancy loss refers to a complete spontaneous abortion or a nonviable pregnancy before 28 weeks of gestation.

  8. Incidence of moderate to severe ovarian hyperstimulation syndrome(OHSS) [ Time Frame: 6 months ]
    Number of cycles of moderate to severe OHSS/total number of fresh stimulation cycle.

  9. Cumulative incidence of maternal and neonatal complications during whole gestation and prenatal stage [ Time Frame: 16 months ]
    Number of pregnancies with complications / number of pregnancies; Number of live births with neonatal complications / number of live births;



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 36 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Women ages 18 to 36 years.
  2. Women BMI at least 25kg/m2.
  3. Women who are non-pcos patient(2003 Rotterdam criteria).
  4. Women with insulin resistance (HOMA criteria).
  5. Women who are participating in their first or second fresh embryo cycle of in- vitro fertilization(IVF) or intracytoplasmic sperm injection (ICSI).
  6. Women who are indicated IVF or ICSI.

Exclusion Criteria:

  1. Women with endometriosis.
  2. Women with untreated hydrosalpinx.
  3. Women with a uterine cavity abnormality, such as a uterine congenital malformation; untreated uterine septum(except shallow uterine septum), adenomyosis, submucous myoma, or intrauterine adhesions.
  4. Women who are indicated and planned to undergo preimplantation genetic diagnosis(PGD)/preimplantation genetic screening(PGS).
  5. Women with endocrine abnormalities, such as Cushing syndrome, congenital adrenal hyperplasia, pituitary amenorrhea, thyroid dysfunction etc.
  6. Women who had participated in other treatments known to affect diet or weight (such as diet drugs and dietitian intervention) for past 3 months.
  7. Women who are unable to follow verbal and written instructions.
  8. Women who use donated oocytes to achieve pregnancy.
  9. Women with poor ovarian response(Bologna criteria).
  10. Women with diabetes mellitus, abnormal glycosylated hemoglobin.
  11. Women who has a history of recurrent spontaneous abortion.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03898037


Locations
Layout table for location information
China, Hunan
Reproductive & Genetic Hospital of CITIC-XIANGYA Recruiting
Changsha, Hunan, China, 410008
Contact: xiaojuan wang    +86-731-82355100    zxxykyb@163.com   
Sponsors and Collaborators
Reproductive & Genetic Hospital of CITIC-Xiangya

Layout table for additonal information
Responsible Party: Reproductive & Genetic Hospital of CITIC-Xiangya
ClinicalTrials.gov Identifier: NCT03898037     History of Changes
Other Study ID Numbers: P2019001
First Posted: April 1, 2019    Key Record Dates
Last Update Posted: August 9, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Infertility
Infertility, Female
Insulin Resistance
Hyperinsulinism
Glucose Metabolism Disorders
Metabolic Diseases
Genital Diseases, Male
Genital Diseases, Female
Insulin
Insulin, Globin Zinc
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs